adult T-cell leukemia/lymphoma
Conditions
Interventions
Daily administration of 25mg of Lenalidomide after induction therapy until disease progression or intolerance
Sponsors
North Japan Hematology Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis of either aggressive type of ATL 2. Age more than 19 years old 3. Achievement of stable disease, partial remission or complete remission 4. Inegible for stem cell transplantation 5. ECOG performance status 0-2 6. Intact organ function 7. Written informed consent of participation
Exclusion criteria
Exclusion criteria: 1. Positivity for HBs antigen 2. Positivity for HIV antibody 3. Double cancers 4. Administration of lenalidomide so far 5. Using Dialysis 6. Heat failure or ischemic heart disease 7. Acute hepatitis or Liver cirrhosis 8. Active infection 9. Active thrombotic diseases 10. Allergy for thalidomide 11. Pregnant or breast-feeding woman 12. Difficult of adherence for drug administration 13. Severe mental disorder 14.An inappropriate patient judged by the medical attendant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety of consolidation therapy using Lenalidomide | — |
Countries
Japan
Contacts
Public ContactAkio Shigematsu
Sapporo Hokuyu Hospital Department of Hematology
Outcome results
None listed